Mesoblast Limited (MESO) Reiterated at Overweight by Cantor Fitzgerald

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterated an Overweight rating on Mesoblast Limited (NASDAQ: MESO).

The analyst commented, "We've been getting more questions on MESO lately - and the conversation is shifting to valuation and what can drive the next leg from here. Ryoncil has had a strong launch in pediatric SR-aGVHD, but at this point, we think the stock is already pricing in some value for Ryoncil's success beyond pediatrics. That's why the adult phase 3 matters so much from here. The adult opportunity is ~3x larger than pediatrics, according to management, and MESO has been transparent that they see Ryoncil in SR-aGVHD as a >$1B annual U.S. franchise across children + adults. So the adult study isn't all upside from today's valuation, but it does unlock the bulk of that opportunity."

For an analyst ratings summary and ratings history on Mesoblast Limited click here. For more ratings news on Mesoblast Limited click here.

Shares of Mesoblast Limited closed at $15.29 yesterday.

You May Also Be Interested In

• Okta, Inc (OKTA) PT Raised to $235 at DA Davidson Following Oktane 2026
• BMO Capital on Colliers International (CIGI): 'We See Attractive Risk-Reward in the Stock'
• Meta Platforms Inc. (META) PT Raised to $995 at Tigress Financial Partners